Advertisement
FTC
Subscribe to FTC

The Lead

FTC Seeks More Info From Pfizer About Hospira Acquisition

May 15, 2015 12:04 pm | by Pfizer Inc. | News | Comments

Pfizer Inc. today announced that it has received a request for additional information from the FTC with respect to its previously announced proposed acquisition of Hospira.

FTC Clears Sun Pharma's $4B Purchase of Ranbaxy

January 30, 2015 2:44 pm | News | Comments

Sun Pharmaceuticals will sell the rights to one generic drug as part of its purchase of...

Lilly Closes Novartis Deal to Create Huge Animal Health Business

January 2, 2015 8:17 am | News | Comments

Just over a week after saying it would sell its heartworm treatment for dogs at the request of...

Eli Lilly to Sell Heartworm Line for Novartis Deal Approval

December 22, 2014 2:20 pm | News | Comments

The Federal Trade Commission is requiring the sale of Eli Lilly's Sentinel heartworm products...

View Sample

FREE Email Newsletter

Soaring Generic Drug Prices Draw Senate Scrutiny

November 20, 2014 8:35 am | by MATTHEW PERRONE, AP Health Writer | News | Comments

Some low-cost generic drugs that have helped restrain health care costs for decades are seeing unexpected price spikes of up to 8,000 percent, prompting a backlash from patients, pharmacists and now Washington lawmakers.     

FTC Sues Gerber Over Claims on Infant Formula

October 30, 2014 2:02 pm | by ANNE FLAHERTY, Associated Press | News | Comments

Federal regulators announced Thursday they were suing Gerber, the well-known baby food maker, for claiming that its Good Start Gentle formula can prevent or reduce allergies in children.           

FTC to Retailers: Drop Your Caffeinated Drawers

October 1, 2014 8:06 am | by JONATHAN J. COOPER, Associated Press | News | Comments

If you purchased caffeine-infused underwear because of promises it will make you thinner, federal regulators say you were hoodwinked — but at least you can get your money back.             

Advertisement

FTC Sues AbbVie, Teva Over Generic AndroGel

September 8, 2014 1:59 pm | News | Comments

The FTC says AbbVie and its partner and Besins Healthcare filed baseless patent infringement lawsuits against Teva Pharmaceutical Industries Ltd. and Perrigo Co. to delay the approval and sale of less-expensive generic versions of the drug.  

FTC Cracks Down on Weight-Loss Scams

January 9, 2014 10:26 am | Videos | Comments

CNN reports on the FTC's crackdown on weight-loss products for deceptive advertising.                           

FTC Asks for More Info for Actavis Acquisition

July 11, 2013 11:23 am | News | Comments

Actavis announced that federal regulators have requested additional information related to its planned acquisition of fellow drugmaker Warner Chilcott PLC. The $8.5 billion all-stock deal originally announced in May would create the third-biggest specialty pharmaceutical company in the U.S. market.

Hedge Fund Manager Applauds Call for Herbalife Investigation

March 13, 2013 7:51 am | News | Comments

Hedge fund manager William Ackman is applauding a consumer group's push for the Federal Trade Commission to investigate whether Herbalife is a pyramid scheme. The National Consumers League said that it wants the FTC to investigate the claims against Herbalife as well as the vitamin and supplement products company's responses.

FTC Study: In FY 2012, Branded Drug Firms Significantly Increased the Use of Potential Pay-for-Delay Settlements to Keep Generic Competitors off the Market

January 17, 2013 9:21 am | by Federal Trade Commission | News | Comments

Record Number of Agreements Cover 31 Different Products, With Combined Annual U.S. Sales of More Than $8.3 Billion

Advertisement

FTC Upholds Decision Against POM Wonderful

January 17, 2013 3:08 am | News | Comments

The Federal Trade Commission has upheld a judge's earlier decision that POM Wonderful made deceptive claims about the health benefits of its products.

FTC Approves Final Order Settling Charges That Watson Pharmaceuticals, Inc.'s Acquisition of Actavis Inc. Would Have Been Anticompetitive

December 14, 2012 6:21 am | by Federal Trade Commission | News | Comments

Following a public comment period, the Federal Trade Commission has approved a final order settling charges that Watson Pharmaceuticals, Inc.?s proposed acquisition of Actavis Inc. would have been anticompetitive in the markets for 21 current and future generic drugs used to treat a wide...

FTC Staff Opinion: The Methodist Hospital System May Sell Discounted Shortage Drugs to Baytown EMS as an Emergency Humanitarian Gesture; FTC Approves Final Order Settling Char...

November 30, 2012 7:20 am | by Federal Trade Commission | News | Comments

In a letter issued today, the staff of the Federal Trade Commission advised The Methodist Hospital System that its proposal to resell pharmaceuticals it purchased at a discount to Baytown EMS is a permissible emergency humanitarian gesture. Following a public comment period, the Federal...

FTC Files Amicus Brief Explaining That Pharmaceutical "Product Hopping" Can Be the Basis for an Antitrust Lawsuit

November 27, 2012 7:21 am | by Federal Trade Commission | News | Comments

The Federal Trade Commission filed an amicus brief before the U.S. District Court for the Eastern District of Pennsylvania explaining that minor, non-therapeutic changes to a branded pharmaceutical product that harm generic competition can constitute exclusionary conduct that violates...

FTC Places Conditions on Watson Pharmaceutical's Proposed Acquisition of Actavis

October 15, 2012 1:21 pm | by Federal Trade Commission | News | Comments

To Protect Competition, Companies Agree to Sell Rights and Assets to 18 Drugs to Sandoz and Par, Relinquish Manufacturing and Marketing Rights for Three Other Drugs

Advertisement

FTC Submits Amicus Brief Explaining that Drug Companies Use ?No-Authorized Generic? Agreements to Delay Generic Competition

October 9, 2012 6:21 am | by Federal Trade Commission | News | Comments

The Federal Trade Commission filed an amicus brief in the U.S. District Court for the District of New Jersey stating that an agreement by a branded drug company not to launch an authorized generic (AG) drug ?provides a convenient method for branded drug firms to pay generic patent...

FTC Seeks U.S. Supreme Court Review in AndroGel "Pay-for-Delay" Case

October 4, 2012 1:21 pm | by Federal Trade Commission | News | Comments

Solicitor General of the United States Files Petition on Behalf of the Agency

Medifast to Pay $3.7M to Settle FTC Charges

September 10, 2012 8:21 am | by Federal Trade Commission | News | Comments

Unsupported Weight-Loss Claims Violated Previous Order, Agency Alleges

FTC to Return Money to Victims of Allegedly Deceptive Drug Price Claims by CVS Caremark

September 4, 2012 7:21 am | by Federal Trade Commission | News | Comments

The FTC will provide refunds to nearly 13,000 consumers who paid significantly more for their drugs than they expected based on allegedly deceptive pricing claims made by CVS Caremark.

FTC Files Amicus Brief Explaining That "No-AG" Agreements Are Used by Drug Companies to Delay Generic Competition

August 13, 2012 8:20 am | by Federal Trade Commission | News | Comments

The Federal Trade Commission filed an amicus brief before the U.S. District Court for the District of New Jersey explaining that an agreement by a branded company not to launch an authorized generic (AG) drug is a ?convenient method? for branded drug firms to pay generic patent...

FTC Staff Issues Advisory Opinion Regarding Generic Pharmaceutical Association's Proposed Initiative to Address Drug Shortages

August 8, 2012 11:20 am | by Federal Trade Commission | News | Comments

Program's Numerous Safeguards Make It Unlikely to Harm Competition

Statement by Federal Trade Commission Chairman Jon Leibowitz on the U.S. Court of Appeals for the Third Circuit Ruling in the K-Dur 20 Matter

July 16, 2012 9:20 am | by Federal Trade Commission | News | Comments

Federal Trade Commission Chairman Jon Leibowitz issued the following statement regarding a key ruling issued today by a panel of the U.S. Court of Appeals for the Third Circuit regarding the legality of patent settlements between branded and generic manufacturers of the high blood...

FTC Puts Conditions on Novartis AG's Acquisition of Fougera Holdings, Inc.

July 16, 2012 8:21 am | by Federal Trade Commission | News | Comments

Settlement Order Protects Competition in the Markets for Skin Care Gels and Cream

FTC Approves Amended Final Order Settling Charges that Teva's Proposed Acquisition of Cephalon was Anticompetitive in Markets for Several Generic Drugs

July 3, 2012 7:21 am | by Federal Trade Commission | News | Comments

Following a public comment period, the Federal Trade Commission has approved an amended final order settling charges that Teva Pharmaceutical Industries, Ltd.'s proposed acquisition of rival Cephalon, Inc. would have been anticompetitive in the markets for several current and future generic drugs.

FTC Issues Modified Final Order Settling Charges that Perrigo's Acquisition of Paddock Laboratories Was Anticompetitive in Market for Generic Pharmaceuticals

June 26, 2012 9:21 am | by Federal Trade Commission | News | Comments

Following a public comment period, the Federal Trade Commission has issued a modified final order settling charges that Perrigo Company's $540 million acquisition of Paddock Laboratories, Inc., as proposed, was anticompetitive and would have reduced the number of manufacturers for four...

FTC Approves Final Settlement with CVS Caremark

May 15, 2012 7:21 am | by Federal Trade Commission | News | Comments

Following a public comment period, the FTC has accepted as final an order with CVS Caremark settling charges that it misrepresented the prices of certain Medicare Part D prescription drugs, including drugs used to treat breast cancer symptoms and epilepsy, at CVS and Walgreens pharmacies.

FTC Chairman Releases 2012 Annual Highlights

March 30, 2012 6:21 am | by Federal Trade Commission | News | Comments

Federal Trade Commission Chairman Jon Leibowitz released the agency?s 2012 Annual Highlights today at the spring meeting of the American Bar Association?s Section of Antitrust Law in Washington, DC, recognizing the agency?s continued efforts to protect consumers and promote competition.

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading